Assetmark, Inc Intra Cellular Therapies, Inc. Transaction History
Assetmark, Inc
- $30.5 Billion
- Q1 2024
A detailed history of Assetmark, Inc transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 2,027 shares of ITCI stock, worth $140,004. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,027
Previous 2,236
9.35%
Holding current value
$140,004
Previous $160,000
12.5%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ITCI
# of Institutions
381Shares Held
77.7MCall Options Held
1.7MPut Options Held
1.13M-
Vanguard Group Inc Valley Forge, PA9.23MShares$637 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.08MShares$558 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$266 Million1.4% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.82MShares$195 Million3.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.48MShares$171 Million2.06% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $6.52B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...